Additionally, studies have suggested a potential role of MG-132 in the treatment of pancreatic cancer, by reducing the expression of TRAF6 in tumor tissue and delaying tumor growth [48]. This evidence concerns the gene TRAF6 and familial pancreatic carcinoma.